European Thyroid Journal最新文献

筛选
英文 中文
Prognostic factors of papillary and follicular carcinomas based on pre-, intra-, and post-operative findings. 基于术前、术中和术后发现的乳头状癌和滤泡状癌预后因素。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-10-04 Print Date: 2024-10-01 DOI: 10.1530/ETJ-24-0196
Yasuhiro Ito, Akira Miyauchi
{"title":"Prognostic factors of papillary and follicular carcinomas based on pre-, intra-, and post-operative findings.","authors":"Yasuhiro Ito, Akira Miyauchi","doi":"10.1530/ETJ-24-0196","DOIUrl":"10.1530/ETJ-24-0196","url":null,"abstract":"<p><strong>Graphical abstract: </strong></p><p><strong>Abstract: </strong>Papillary and follicular thyroid carcinomas (PTC and FTC) are prominent malignancies that originate from thyroid follicular cells. PTC is usually diagnosed via preoperative cytology, and large tumor size, clinical node metastasis, and distant metastasis constitute preoperative prognostic factors. Gross extrathyroidal and extranodal tumor extensions have a significant prognostic impact, are evaluated intraoperatively, and are useful for determining the extent of surgery. Aggressive variants, such as tall cell and hobnail variants, a high Ki-67 labeling index (LI), and somatic gene mutations are prognostic factors in postoperative pathological and molecular examinations. In contrast, FTC is generally diagnosed based on postoperative pathology. Large tumor size and M factors have prognostic value; however, the findings of pathological examinations are very important. FTCs are classified as minimally invasive, encapsulated angioinvasive, and widely invasive FTCs. Widely invasive FTC with vascular invasion (VI) and encapsulated angioinvasive FTCs with extensive VI have a poor prognosis, whereas widely invasive FTC without VI has an excellent prognosis, which is similar to that of minimally invasive FTC. This indicates that VI is a considerably more important prognostic marker than capsular invasion. For postoperative follow-up, dynamic markers such as the thyroglobulin-doubling rate (DR), metastatic tumor volume-DR, and change in the neutrophil-to-lymphocyte ratio are important and are useful for evaluating the effectiveness of treatments, such as radioactive iodine therapy and molecular targeted therapy, for recurrent lesions. For clinicians, it is important to accurately evaluate prognostic markers of PTC and FTC in the pre-, intra-operative, and post-operative phases.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between BMI and BRAFV600E mutation may differ by primary tumor size. BMI 与 BRAFV600E 基因突变之间的关系可能因原发性肿瘤大小而异。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-10-03 Print Date: 2024-10-01 DOI: 10.1530/ETJ-23-0255
Hyunju Park, Jung Heo, Hyun Jin Ryu, Min-Ji Kim, Young Lyun Oh, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung
{"title":"The association between BMI and BRAFV600E mutation may differ by primary tumor size.","authors":"Hyunju Park, Jung Heo, Hyun Jin Ryu, Min-Ji Kim, Young Lyun Oh, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung","doi":"10.1530/ETJ-23-0255","DOIUrl":"10.1530/ETJ-23-0255","url":null,"abstract":"<p><strong>Objective: </strong>Previous reports suggest that a high body mass index (BMI) increases the risk of thyroid carcinoma. However, it remains unclear whether a high BMI is associated with the risk of the BRAFV600E mutation. We aimed to assess whether a high BMI is associated with an increased risk of the BRAFV600E mutation.</p><p><strong>Design and methods: </strong>We screened 6558 PTC patients who had undergone BRAFV600E mutation testing between January 2009 and December 2017. After exclusion, 6438 PTC patients were enrolled. We used logistic regression, and restricted cubic spline plots of the adjusted odds ratios (ORs) were illustrated to model the relationship between BMI and the BRAFV600E mutation.</p><p><strong>Results: </strong>Of the 6438 patients, 5102 (79.2%) had the BRAFV600E mutation, and 4954 (76.9%) were female. The median BMI was 23.8 (21.6-26.2) kg/m2. The primary tumor size was ≤1 cm in 4226 patients (65.6%) and >1 cm in 2212 patients (34.4%). The BRAFV600E mutation was significantly associated with high BMI only in patients with a primary tumor size >1 cm (OR: 1.034; 95% CI: 1.003-1.065; P = 0.029), whereas no clear association was found in patients with a primary tumor size ≤1 cm (OR: 1.007; 95% CI: 0.984-1.030; P = 0.570). Gender was not a significant factor in either group.</p><p><strong>Conclusions: </strong>Our study found that a higher BMI was positively associated with the BRAFV600E mutation in patients with a primary tumor size >1 cm. These results suggest that the association between BMI and the BRAFV600E mutation status differs depending on primary tumor size.</p><p><strong>Significance statement: </strong>Obesity has been suggested as a potential risk factor for thyroid carcinoma. The aim of this study was to assess the association between BMI and the BRAFV600E mutation. In this study, the BRAFV600E mutation was significantly associated with a high BMI only in a primary tumor size >1 cm (OR: 1.034; P = 0.029). No clear association was found in patients with a primary tumor size ≤1 cm (OR: 1.007; P = 0.570). The association between BMI and the BRAFV600E mutation status differs depending on the primary tumor size.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Haemodynamics of hyperthyroidism: increased cardiac work and findings related to vasodilatation. 甲状腺功能亢进症的血液动力学:心脏做功增加以及与血管扩张有关的研究结果。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-10-01 DOI: 10.1530/ETJ-24-0090
Nelli Suonsyrjä, Saara Metso, Eeva Moilanen, Jukka Mustonen, Pia Jaatinen, Ilkka Pörsti
{"title":"Haemodynamics of hyperthyroidism: increased cardiac work and findings related to vasodilatation.","authors":"Nelli Suonsyrjä, Saara Metso, Eeva Moilanen, Jukka Mustonen, Pia Jaatinen, Ilkka Pörsti","doi":"10.1530/ETJ-24-0090","DOIUrl":"https://doi.org/10.1530/ETJ-24-0090","url":null,"abstract":"<p><strong>Objective: </strong>Hyperthyroidism increases cardiovascular morbidity and mortality, but the underlying mechanisms are not fully understood. In this study we compared non-invasive haemodynamics between 20 hyperthyroid patients and 60 euthyroid subjects.</p><p><strong>Methods: </strong>The measurements were performed median 6 days after the initiation of antithyroid medication when the patients were still hyperthyroid. Three controls matched for age, sex, body mass index, and smoking status were selected for each patient. Recordings were performed during rest and passive head-up tilt using whole-body impedance cardiography, radial pulse wave analysis, and finger blood pressure measurements.</p><p><strong>Results: </strong>Systolic and diastolic blood pressures in the aorta and radial artery were similar in hyperthyroid and euthyroid subjects, while finger blood pressure was 16/12 mmHg lower in hyperthyroidism (p<0.001). Pulse wave velocity and aortic pulse pressure were similar, but radial pulse pressure was ~5 mmHg higher in hyperthyroidism (p=0.040) due to augmented amplification (p=0.045). Systemic vascular resistance was reduced (-18%), whereas heart rate (+19 beats/min), cardiac index (+28%), and left cardiac work (+31%) were increased in hyperthyroidism (p<0.001). Subendocardial viability ratio, reflecting the balance between coronary perfusion and pressure load, was reduced by 19% in hyperthyroidism (p<0.001). Compared with euthyroid subjects, hyperthyroid patients presented with reductions in systolic and diastolic finger blood pressures (p<0.001), and higher increase in heart rate (p=0.014) during upright posture.</p><p><strong>Conclusions: </strong>Hyperthyroid patients exhibited hyperdynamic circulation, reduced vascular resistance, reduced peripheral but not central blood pressure, and higher pulse pressure amplification. Furthermore, left cardiac workload was increased in parallel with unfavourable changes in coronary perfusion conditions.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic regulation of thyroid hormone action in human metabolic dysfunction-associated steatohepatitis. 人类代谢功能障碍相关性脂肪性肝炎中甲状腺激素作用的表观遗传调控。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-09-21 Print Date: 2024-10-01 DOI: 10.1530/ETJ-24-0080
Alison-Michelle Naujack, Christin Krause, Jan H Britsemmer, Natalie Taege, Jens Mittag, Henriette Kirchner
{"title":"Epigenetic regulation of thyroid hormone action in human metabolic dysfunction-associated steatohepatitis.","authors":"Alison-Michelle Naujack, Christin Krause, Jan H Britsemmer, Natalie Taege, Jens Mittag, Henriette Kirchner","doi":"10.1530/ETJ-24-0080","DOIUrl":"10.1530/ETJ-24-0080","url":null,"abstract":"<p><strong>Objective: </strong>Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by inflammation, fibrosis, and accumulation of fatty acids in the liver. MASH disease progression has been associated with reduced thyroid hormone (TH) signaling in the liver, including reduced expression of deiodinase type I (DIO1) and TH receptor beta (THRB). However, the underlying mechanisms mediating these effects remain elusive. Here, we hypothesized that epigenetic mechanisms may be involved in modulating hepatic TH action.</p><p><strong>Methods: </strong>Liver samples from patients with and without MASH were analyzed by qRT-PCR and correlated with clinical parameters. Luciferase reporter assays and overexpression of miRNA in HepG2 cells were used to validate the functional binding of miRNA to predicted targets. DNA methylation was analyzed by bisulfite pyrosequencing.</p><p><strong>Results: </strong>miR-34a-5p was upregulated in MASH patients and correlated positively with the clinical parameters of MASH. Using in silico and in vitro analysis, we demonstrate that miR-34a-5p is capable of targeting several modulators of local hepatic TH action, as evidenced by the functional binding of miR-34a-5p to the seed sequence in the THRB and DIO1 genes. Consequently, overexpression of miR-34a-5p in HepG2 cells reduced the expression of THRA, THRB, DIO1, and SLC10A1, thus potentially mediating an acquired hepatic resistance to TH in MASH. As an additional regulatory mechanism, DNA methylation of THRB intron 1 was increased in MASH and negatively correlated with THRB expression.</p><p><strong>Conclusion: </strong>miR-34a-5p constitutes a possible epigenetic master regulator of hepatic TH action, which together with THRB-specific DNA methylation could explain a possible developing TH resistance in the liver during MASH progression on the molecular level.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib. 接受舍帕替尼治疗的RET突变型甲状腺髓样癌患者出现波动性闭塞性支气管炎。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-09-19 Print Date: 2024-10-01 DOI: 10.1530/ETJ-24-0189
Carla Gambale, Alessandro Prete, Chiara Romei, Alessandro Celi, Rossella Elisei, Antonio Matrone
{"title":"Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib.","authors":"Carla Gambale, Alessandro Prete, Chiara Romei, Alessandro Celi, Rossella Elisei, Antonio Matrone","doi":"10.1530/ETJ-24-0189","DOIUrl":"10.1530/ETJ-24-0189","url":null,"abstract":"<p><p>Highly selective RET inhibitor selpercatinib has demonstrated notable efficacy in advanced/progressive RET-mutant medullary thyroid cancer (MTC) patients. However, despite a more tolerable toxicity profile than multikinase inhibitors, peculiar adverse events (AEs) have been described. Obliterative bronchiolitis (OB) is a respiratory disease characterized by inflammation and fibrosis in small conducting airways. We evaluated a 70-year-old man with advanced RET-mutant MTC who developed OB during treatment with selpercatinib. Radiological features of OB occurred early and persisted during selpercatinib treatment, with a waxing and waning pattern. Notably, a partial response of MTC was achieved during the treatment, and selpercatinib was never reduced or interrupted. The almost complete absence of symptoms and the fluctuating trend, without specific treatment for OB, suggested that it is necessary to carefully evaluate the risks mediated by this AE with the risks of modifying or discontinuing the anti-cancer therapy.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decreased sirtuin 4 levels promote cellular proliferation and invasion in papillary thyroid carcinoma. Sirtuin 4 水平降低会促进甲状腺乳头状癌的细胞增殖和侵袭
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-09-16 Print Date: 2024-10-01 DOI: 10.1530/ETJ-24-0079
Hyun-Jin Lee, Young-Sool Hah, So Young Cheon, Seong Jun Won, Chae Dong Yim, Somi Ryu, Seung-Jun Lee, Ji Hyun Seo, Jung Je Park
{"title":"Decreased sirtuin 4 levels promote cellular proliferation and invasion in papillary thyroid carcinoma.","authors":"Hyun-Jin Lee, Young-Sool Hah, So Young Cheon, Seong Jun Won, Chae Dong Yim, Somi Ryu, Seung-Jun Lee, Ji Hyun Seo, Jung Je Park","doi":"10.1530/ETJ-24-0079","DOIUrl":"10.1530/ETJ-24-0079","url":null,"abstract":"<p><strong>Objective: </strong>This study examined the effect of sirtuin 4 (SIRT4), a NAD+-dependent deacetylase, on the proliferation and progression of papillary thyroid carcinoma (PTC).</p><p><strong>Methods: </strong>Data from The Cancer Genome Atlas (TCGA) were analyzed to identify SIRT4 expression in thyroid cancer. Subsequently, the correlation between SIRT4 expression and clinical characteristics was examined in 205 PTC tissue samples. In vitro assays using three human thyroid cancer cell lines (B-CPAP, TPC-1, and SNU-790) were conducted to assess the effects of regulated SIRT4 expression on cell growth, apoptosis, invasion, and migration. Furthermore, in vivo experiments were performed in a xenograft mouse model.</p><p><strong>Results: </strong>Gene Expression Omnibus (GEO) and TCGA data indicated that SIRT4 expression is lower in thyroid cancer and SIRT4 downregulation is associated with poor overall survival. In PTC tissues, positive SIRT4 expression was associated with decreased extracapsular extension. In in vitro experiments using three human thyroid cancer cell lines, overexpression of SIRT4 decreased cell survival, clonogenic potential, and invasion and migratory capabilities, as well as inducing apoptosis and increasing reactive oxygen species levels. SIRT4 overexpression upregulated E-cadherin and downregulated N-cadherin, suggesting its potential involvement in the regulation of epithelial-mesenchymal transition. These findings were confirmed in vivo using a xenograft mouse model.</p><p><strong>Conclusion: </strong>This study provides novel insight into the potential contribution of SIRT4 to the regulation of the pathological progression of PTC. The data suggest that SIRT4 plays a tumor-suppressive role in PTC by inhibiting growth, survival, and invasive potential. Future research should investigate the molecular mechanisms underlying these effects of SIRT4.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141909833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decreased sirtuin 4 levels promote cellular proliferation and invasion in papillary thyroid carcinoma. 甲状腺乳头状癌中sirtuin 4水平的降低会促进细胞增殖和侵袭。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-09-16 Print Date: 2024-10-01 DOI: 10.1530/ETJ-24-0079
Hyun-Jin Lee, Young-Sool Hah, So Young Cheon, Seong Jun Won, Chae Dong Yim, Somi Ryu, Seung-Jun Lee, Ji Hyun Seo, Jung Je Park
{"title":"Decreased sirtuin 4 levels promote cellular proliferation and invasion in papillary thyroid carcinoma.","authors":"Hyun-Jin Lee, Young-Sool Hah, So Young Cheon, Seong Jun Won, Chae Dong Yim, Somi Ryu, Seung-Jun Lee, Ji Hyun Seo, Jung Je Park","doi":"10.1530/ETJ-24-0079","DOIUrl":"10.1530/ETJ-24-0079","url":null,"abstract":"<p><strong>Objective: </strong>This study examined the effect of sirtuin 4 (SIRT4), a NAD+-dependent deacetylase, on the proliferation and progression of papillary thyroid carcinoma (PTC).</p><p><strong>Methods: </strong>Data from The Cancer Genome Atlas (TCGA) were analyzed to identify SIRT4 expression in thyroid cancer. Subsequently, the correlation between SIRT4 expression and clinical characteristics was examined in 205 PTC tissue samples. In vitro assays using three human thyroid cancer cell lines (B-CPAP, TPC-1, and SNU-790) were conducted to assess the effects of regulated SIRT4 expression on cell growth, apoptosis, invasion, and migration. Furthermore, in vivo experiments were performed in a xenograft mouse model.</p><p><strong>Results: </strong>Gene Expression Omnibus (GEO) and TCGA data indicated that SIRT4 expression is lower in thyroid cancer and SIRT4 downregulation is associated with poor overall survival. In PTC tissues, positive SIRT4 expression was associated with decreased extracapsular extension. In in vitro experiments using three human thyroid cancer cell lines, overexpression of SIRT4 decreased cell survival, clonogenic potential, and invasion and migratory capabilities, as well as inducing apoptosis and increasing reactive oxygen species levels. SIRT4 overexpression upregulated E-cadherin and downregulated N-cadherin, suggesting its potential involvement in the regulation of epithelial-mesenchymal transition. These findings were confirmed in vivo using a xenograft mouse model.</p><p><strong>Conclusion: </strong>This study provides novel insight into the potential contribution of SIRT4 to the regulation of the pathological progression of PTC. The data suggest that SIRT4 plays a tumor-suppressive role in PTC by inhibiting growth, survival, and invasive potential. Future research should investigate the molecular mechanisms underlying these effects of SIRT4.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease. 甲状腺眼病患者静脉注射糖皮质激素治疗反应的预测模型。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-08-26 Print Date: 2024-08-01 DOI: 10.1530/ETJ-24-0122
Haiyang Zhang, Shuo Wu, Shuyu Hu, Xianqun Fan, Xuefei Song, Tienan Feng, Huifang Zhou
{"title":"Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease.","authors":"Haiyang Zhang, Shuo Wu, Shuyu Hu, Xianqun Fan, Xuefei Song, Tienan Feng, Huifang Zhou","doi":"10.1530/ETJ-24-0122","DOIUrl":"10.1530/ETJ-24-0122","url":null,"abstract":"<p><strong>Background: </strong>Thyroid eye disease (TED) is an autoimmune orbital disease, with intravenous glucocorticoid (IVGC) therapy as the first-line treatment. Due to uncertain response rates and possible side effects, various prediction models have been developed to predict IVGC therapy outcomes.</p><p><strong>Methods: </strong>A thorough search was conducted in PubMed, Embase, and Web of Science databases. Data extraction included publication details, prediction model content, and performance. Statistical analysis was performed using R software, including heterogeneity evaluation, publication bias, subgroup analysis, and sensitivity analysis. Forest plots were utilized for result visualization.</p><p><strong>Results: </strong>Of the 12 eligible studies, 47 prediction models were extracted. All included studies exhibited a low-to-moderate risk of bias. The pooled area under the receiver operating characteristic curve (AUC) and the combined sensitivity and specificity for the models were 0.81, 0.75, and 0.79, respectively. In view of heterogeneity, multiple meta-regression and subgroup analysis were conducted, which showed that marker and modeling types may be the possible causes of heterogeneity (P < 0.001). Notably, imaging metrics alone (AUC = 0.81) or clinical characteristics combined with other markers (AUC = 0.87), incorporating with multivariate regression (AUC = 0.84) or radiomics analysis (AUC = 0.91), yielded robust and reliable prediction outcomes.</p><p><strong>Conclusion: </strong>This meta-analysis comprehensively reviews the predictive models for IVGC therapy response in TED. It underscores that integrating clinical characteristics with laboratory or imaging indicators and employing advanced techniques like multivariate regression or radiomics analysis significantly enhance the efficacy of prediction. Our research findings offer valuable insights that can guide future studies on prediction models for IVGC therapy in TED.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A post-irradiation-induced replication stress promotes RET proto-oncogene breakage. 辐照后诱导的复制应激促进了 RET 原癌基因的断裂。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-08-23 Print Date: 2024-08-01 DOI: 10.1530/ETJ-24-0028
Fabio Hecht, Laura Valerio, Carlos Frederico Lima Gonçalves, Marylin Harinquet, Rabii Ameziane El Hassani, Denise P Carvalho, Stephane Koundrioukoff, Jean-Charles Cadoret, Corinne Dupuy
{"title":"A post-irradiation-induced replication stress promotes RET proto-oncogene breakage.","authors":"Fabio Hecht, Laura Valerio, Carlos Frederico Lima Gonçalves, Marylin Harinquet, Rabii Ameziane El Hassani, Denise P Carvalho, Stephane Koundrioukoff, Jean-Charles Cadoret, Corinne Dupuy","doi":"10.1530/ETJ-24-0028","DOIUrl":"10.1530/ETJ-24-0028","url":null,"abstract":"<p><strong>Objective: </strong>Ionizing radiation generates genomic instability by promoting the accumulation of chromosomal rearrangements. The oncogenic translocation RET/PTC1 is present in more than 70% of radiation-induced thyroid cancers. Both RET and CCDC6, the genes implicated in RET/PTC1, are found within common fragile sites - chromosomal regions prone to DNA breakage during slight replication stress. Given that irradiated cells become more susceptible to genomic destabilization due to the accumulation of replication-stress-related double-strand breaks (DSBs), we explored whether RET and CCDC6 exhibit DNA breakage under replicative stress several days post-irradiation of thyroid cells.</p><p><strong>Methods: </strong>We analyzed the dynamic of DNA replication in human thyroid epithelial cells (HThy-ori-3.1) 4 days post a 5-Gy exposure using molecular DNA combing. The DNA replication schedule was evaluated through replication-timing experiments. We implemented a ChIP-qPCR assay to determine whether the RET and CCDC6 genes break following irradiation.</p><p><strong>Results: </strong>Our study indicates that replicative stress, occurring several days post-irradiation in thyroid cells, primarily causes DSBs in the RET gene. We discovered that both the RET and CCDC6 genes undergo late replication in thyroid cells. However, only RET's replication rate is notably delayed after irradiation.</p><p><strong>Conclusion: </strong>The findings suggest that post-irradiation in the RET gene causes a breakage in the replication fork, which could potentially invade another genomic area, including CCDC6. As a result, this could greatly contribute to the high prevalence of chromosomal RET/PTC rearrangements seen in patients exposed to external radiation.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma. 地高辛治疗不会重新诱导放射性碘难治性非髓性甲状腺癌的放射性碘摄取。
IF 3.5 2区 医学
European Thyroid Journal Pub Date : 2024-08-19 Print Date: 2024-08-01 DOI: 10.1530/ETJ-24-0153
Pepijn van Houten, James Nagarajah, Janneke E W Walraven, Martin Jaeger, Adriana C H van Engen-van Grunsven, Johannes W Smit, Romana T Netea-Maier
{"title":"Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma.","authors":"Pepijn van Houten, James Nagarajah, Janneke E W Walraven, Martin Jaeger, Adriana C H van Engen-van Grunsven, Johannes W Smit, Romana T Netea-Maier","doi":"10.1530/ETJ-24-0153","DOIUrl":"10.1530/ETJ-24-0153","url":null,"abstract":"<p><strong>Objective: </strong>Patients with non-medullary thyroid carcinoma (NMTC) that are refractory to radioactive iodine (RAI) have a poor prognosis. Strategies for restoring the ability to take up iodine, so-called redifferentiation, are promising but not suitable for all patients. Preclinical studies, in human cell lines just as in a murine model, have shown that the cardiac glycoside digoxin restored RAI uptake. This prospective single-center open-label study aimed to investigate whether treatment with digoxin could reinduce clinically relevant RAI uptake in patients with metastasized RAI-refractory NMTC.</p><p><strong>Methods: </strong>Eight patients with metastasized RAI-refractory NMTC were included between November 2022 and June 2023. Before treatment, a baseline [123I]NaI scintigraphy was performed. Thereafter, patients were treated with digoxin for 3 weeks. Starting doses depended on age and weight. For safety reasons, the usual therapeutic range was aimed for. After 1 week, the digoxin plasma concentration was measured, and the digoxin dose was adjusted if necessary. After 3 weeks of digoxin treatment, a second [123I]NaI scintigraphy was performed. RAI uptake was compared between the two scintigraphies.</p><p><strong>Results: </strong>Seven patients completed the digoxin treatment and were evaluable. None of the seven patients showed clinically relevant RAI uptake after digoxin treatment. No digoxin-related serious adverse events occurred during this trial.</p><p><strong>Conclusion: </strong>Contrary to results from preclinical trials, in this trial, 3 weeks of digoxin treatment did not reinduce RAI uptake in patients with NMTC. This highlights essential challenges regarding the approach toward optimization of studies aimed to restore the RAI uptake and its therapeutic efficacy through drug repurposing.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信